Pognan François, Steger-Hartmann Thomas, Díaz Carlos, Blomberg Niklas, Bringezu Frank, Briggs Katharine, Callegaro Giulia, Capella-Gutierrez Salvador, Centeno Emilio, Corvi Javier, Drew Philip, Drewe William C, Fernández José M, Furlong Laura I, Guney Emre, Kors Jan A, Mayer Miguel Angel, Pastor Manuel, Piñero Janet, Ramírez-Anguita Juan Manuel, Ronzano Francesco, Rowell Philip, Saüch-Pitarch Josep, Valencia Alfonso, van de Water Bob, van der Lei Johan, van Mulligen Erik, Sanz Ferran
Preclinical Safety/Translational Medicine, Novartis, 4057 Basel, Switzerland.
Pharmaceuticals, Investigational Toxicology, Bayer AG, 13342 Berlin, Germany.
Pharmaceuticals (Basel). 2021 Mar 8;14(3):237. doi: 10.3390/ph14030237.
eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events.
eTRANSAFE是一个在创新药物计划（IMI）框架内资助的研究项目，其目标是开发综合数据库和计算工具（eTRANSAFE毒理学中心），通过使用参与该项目的制药公司提供的遗留数据来支持新药的转化安全性评估。该项目的目标包括开发包含临床前和临床数据的数据库、用于转化分析的计算系统（包括数据查询、分析和可视化工具）以及用于解释和预测药物安全事件的计算模型。
